BMP-4 Truncated Peptides Enhancing Osteogenic Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for promoting osteogenesis and chondroinduction in tissues are limited in efficacy, particularly in using truncated growth factors that can effectively interact with bone morphogenic protein receptors to stimulate osteoblast proliferation and differentiation.

Innovation Solution

Development of an isolated polypeptide with a specific amino acid sequence, corresponding to residues 303-408 of BMP-4, which is 100% identical to SEQ ID NO: 2, and its variants, capable of interacting with BMPR type IA and II, and used in compositions with proteases to enhance osteogenic activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If truncated growth factors are used to promote osteogenesis, then the efficacy of stimulating osteoblast proliferation and differentiation is improved, but the ability to effectively interact with bone morphogenic protein receptors is reduced

Engineering Contradiction:

Improveosteogenic activityVSAvoidreceptor interaction capability

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The BMP-4 growth factor is divided into truncated segments (specific amino acid sequences) that retain osteogenic activity while reducing full-length complexity. This segmentation allows the active domains to stimulate osteoblast proliferation and differentiation without requiring the complete receptor interaction profile of the full-length protein.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The amino acid sequence parameters of BMP-4 are modified by truncation to specific residues, changing the molecular weight and structural characteristics while preserving the core osteogenic function. This parameter change enables enhanced productivity in bone tissue regeneration while managing the trade-off in receptor interaction complexity.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If full-length BMP-4 is used, then receptor interaction capability is maintained, but osteogenic efficacy is reduced compared to optimized truncated variants

Engineering Contradiction:

Improvereceptor interaction capabilityVSAvoidosteogenic activity

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The essential osteogenic functional domains are extracted from the full-length BMP-4 sequence, isolating the specific amino acid regions (truncated variants) that provide enhanced osteogenic activity. This extraction removes unnecessary portions of the full-length protein while concentrating the bioactive elements that drive osteoblast proliferation and differentiation.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

Specific local regions of the BMP-4 sequence are optimized for maximal osteogenic effect. The truncated variants focus the biological activity in specific amino acid sequences that locally concentrate the osteoinductive properties, creating higher efficacy in bone formation compared to the distributed activity of the full-length protein.

Inventive Principle:

Principle #3Local quality

3Productivity

If proteases are added to enhance osteogenic activity, then osteoblast differentiation is improved, but the complexity of the composition increases

Engineering Contradiction:

Improveosteoblast differentiationVSAvoidcomposition complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The truncated growth factor peptides are combined with proteases in a single composition to achieve synergistic osteogenic effects. This merging of components allows the proteases to process and activate the truncated peptides in vivo, enhancing osteoblast differentiation while delivering multiple functions through one integrated formulation.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

Proteases act as intermediary enzymes that process the truncated growth factor peptides into their active forms. This intermediary step enables the composition to deliver both the growth factor precursors and the activating enzymes, creating a self-processing system that enhances osteogenic activity while managing composition complexity through functional integration.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The polypeptide composition significantly increases osteogenic activity in bone and connective tissues by promoting osteoblast differentiation and proliferation, with enhanced activity compared to unmodified growth factors, as demonstrated by increased alkaline phosphatase expression in myoblasts.

Implementation Method 1

capable of interacting with BMPR type IA and II

Methodology Applied

Scientific EffectProtein-protein interaction:

Implementation Method 2

promoting osteoblast differentiation and proliferation

Methodology Applied

Scientific EffectSignal transduction:

Implementation Method 3

contacting mature BMP-4 with a collagenase under conditions that promote protein cleavage

Methodology Applied

Scientific EffectProteolytic cleavage: Hydrolysis

Implementation Method 4

increased alkaline phosphatase expression in myoblasts

Methodology Applied

Scientific EffectEnzyme expression induction:

Data Source

PatentEP2550006B1BMP-4 peptides&methods of use

Publication Date: 2018.08.22 LIFENET HEALTH

Figure 1

AI summary

The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.